ARNOLD WHITE & DURKEE
A PROFESSIONAL CORPORATION
ATTORNEYS AT LAW

Austin
Chicago
Houston
Menlo Park
Minneapolis
Washington

1900 One American Center
600 Congress Avenue
Austin, Texas 78701-3248

Telephone 512.418.3000
Facsimile 512.474.7577

Writer's Direct Dial
(512) 418-3184

16X918
DAVIS
1642

September 10, 1998

FILE: CADL:002

VIA HAND-DELIVERY

Assistant Commissioner for Patents
Washington, DC 20231

RE: *USSN 07/431,533 for "URINARY TUMOR ASSOCIATED ANTIGEN, ANTIGENIC SUBUNITS AND METHODS OF DETECTION" by Donald Morton et al. (Attorney Dkt No.: CADL:002/HYL)*

Sir:

Enclosed for filing in the above-referenced patent application is:

(1) A signed Declaration Under 37 C.F.R. § 1.132 of John E. Shively; and

(2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

No fees are believed to be due in connection with the filing of this Declaration; however, should any fees under 37 C.F.R §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Arnold, White & Durkee Deposit Account No. 01-2508/CADL:002/HYL.

Respectfully submitted,

Steven L. Highlander
Registration No. 37,642

encl.

PATENT

#65/AR
09/16/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	§	
	§	
Donald L. MORTON *et al.*	§	
	§	Group Art Unit: 1813
Serial No.: 07/431,533	§	
	§	Examiner: M. Davis
Filed: November 3, 1989	§	
	§	Atty. Dkt.: CADL:002/HYL
For: URINARY TUMOR ASSOCIATED ANTIGEN, ANTIGENIC SUBUNITS AND METHODS OF DETECTION	§	

DECLARATION UNDER 37 C.F.R. §1.132 OF JOHN E. SHIVELY

BOX AF
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, John E. Shively, declare that:

1. I am Chairman of the Division of Immunology at the Beckman Research Institute of the City of Hope. I have held this position for 11 years and have worked on tumor antigens

for 21 years. I also am an expert protein chemist and am familiar with methods of protein purification, characterization, and structural analysis. A copy of my *curriculum vitae* is attached.

2. I have reviewed the abstract of Euhus *et al.*, *24th Annual Meeting of the American Society of Clinical Oncology* proceedings, May 22-24, 1988, and the claims pending in the above-captioned patent application. It is my understanding that the examiner in charge of the above-captioned application has alleged that the Euhus abstract enables one skilled in the arts of protein purification to isolate UTAA (urinary tumor associated antigen) from the sera of melanoma patients.

3. As an expert in the field, I believe that the Euhus abstract does not contain sufficient information to enable purification of UTAA. Furthermore, based on a comparison of this abstract and subsequent articles (Euhus *et al.*, *Int. J. Cancer*, 45:1065-1070, 1990, and Euhus *et al.*, *Cancer Immunol. Immunother.*, 32:214-220, 1990), it is my opinion that the antigen as described in the abstract was not purified to homogeneity, nor characterized sufficiently to allow even an expert to positively identify the same antigen. This opinion is based on the stated fact in the abstract that UTAA was usually isolated as an antigen-antibody complex in a fraction containing other antibody complexes. Such an unfractionated complex must contain many other antibodies and proteins irrelevant to UTAA and its cognate antibodies. They also state that some sera were free of immune complexes, but insufficient information was given on how to identify such sera, or how to modify the isolation procedure to successfully isolate the antigen under these distinct circumstances. In subsequent articles (cited above), the authors describe further

purification steps and primary evidence (Coomassie Blue stained gels and Western blots) that convincingly establish a method or purification, the purity and the molecular mass of UTAA.

4. While the examiner is correct that molecular masses reported from SDS gels are often in error by 10%, it also is true that this potential error leads to a source of confusion in the identification of proteins from one lab to another. Thus, the specific details of a given protein purification are critical to the establishment of identity of a protein. In the case of UTAA, sufficient detail to reproduce the purification and identification of UTAA was not available until the later, more detailed publications. It is clear to me that the Euhus abstract was a preliminary report, presenting evidence that such an antigen may exist and may be isolated given sufficient work. Indeed, more convincing proof was established in later work.

5. I hereby declare that all statements made herein of my knowledge are true and that all statements made herein on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under § 1001 of Title 18 of the U.S. Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

9/9/98
DATE

John E Shively
JOHN E. SHIVELY

CURRICULUM VITAE

John E. Shively, Ph.D.

Beckman Research Institute of the City of Hope
Division of Immunology
1450 East Duarte Road
Duarte, CA 91010
Telephone (818) 357-9711 (x2601)
Fax (818) 301-8186

Education:

University of Illinois, Urbana - B.S. -1968 - Chemistry
University of Illinois, Urbana - M.S. -1969 - Biochemistry
University of Illinois, Urbana - Ph.D.- 1975 - Biochemistry

Positions:

9/75 - 11/76	Junior Research Scientist, Department of Immunology, City of Hope National Medical Center, Duarte, CA.
11/76 - 7/77	Assistant Research Scientist, Division of Immunology, City of Hope National Medical Center, Duarte, CA.
7/77 - 10/84	Associate Research Scientist, Division of Immunology, City of Hope National Medical Center, Duarte, CA.
7/77 - 12/86	Director of Immunochemistry, Division of Immunology, City of Hope National Medical Center, Duarte, CA.
10/84 -Present	Research Scientist, Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA.
1/87 - Present	Chairman, Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA.

Societies:

American Society of Biological Chemists and Molecular Biologist
American Association for the Advancement of Science
American Association for Cancer Research
Protein Society

Publicatons: John E. Shively, Ph.D.

1. Lewis, M. R. and Shively, J. E. Maleimidocysteinyl-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody hinge sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjugate Chemistry. Vol. 9, 72-86, 1998.

2. Williams, L. E., Lewis, M. R., Bebb, G., Clarke, K. G., Odom-Maryon, T. L., Shively, J. E., and Raubitscheck, A. A. Biodistribution of ^{III}In-labeled and 90Y DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anti-CEA monoclonal antibody in xenograft-bearing nude mice: comparison of stable and chemical labile linker systems. Bioconj. Chem. Vol. 9, 87-93, 1998.

3. Chen, D. S., Ananaka, M., Chen, F. S., Shively, J. E., and Lai, M. M. Human carcinoembryonic antigen and biliary glycoprotein can serve as mouse hepatitis virus receptors. J. Virol. Vol. 71, 1688-1691, 1997.

4. Hefta, J. J. F., Neumaier, M., and Shively, J. E. Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs. Immuno Technology. In Press, 1997.

5. Neumaier, M., Gaida, F.-J., Lewis, M. R., Hefta, L. J., Shively, L. E., Raubitscheck, A., and Shively, J. E. A chimeric anti-CEA antibody with heavy interchain disulfide bonds deleted: Molecular characterization and biodistributions in normal and tumor bearing mice. Submitted, 1997.

6. Neumaier, M., Shively, L. E., Raubitschek, A. A., and Shively, J. E. Expression and biodistributions in xenograft bearing nude mice of a monovalent, heavy chain disulfide bond deleted chimeric anti-carcinoembryonic antigen antibody. Antibody Technology. Submitted, 1997.

7. Wong, J. Y. C., Thomas, G. E., Yamauchi, D., Williams, L. E., Odom-Maryon, T., Esteban, J. M., Neumaier, M., Wu, A. M., Primus, F. J., Shively, J. E., and Raubitscheck, A. A. Clinical evaluation of an ^{111}Indium labeled anti-CEA chimeric monoclonal antibody. J. of Nuc. Med. Vol. 38, 1951-1959, 1997.

8. Chen, C.-J., Lin, T.-T., and Shively, J. E. Role of interferon regulatory Factor-1 in the induction of biliary glycoprotein (Cell CAM-1) by interferon-g. J. Biol. Chem. Vol. 271, 28181-28188, 1996.

9. Hefta, L. J., Wu, A. M., Neumaier, M., and Shively, J. E. Measuring antibody affinity using biosensors. *In:* D. Chriswell, MacCafferty J. and Hoogenboom, H. (ed.) Antibody Engeineering: A Practical Approach, pp. 99-117. London: Oxford Press, 1996.

10. Hu, S., Shively, L., Raubitscheck, A. A., Sherman, M., Williams, L. E., Shively, J. E., and Wu, A. M. Minibody: Rapid imaging of CEA-positive tumors using a novel engineered anti-CEA antibody fragment. Cancer Res. Vol. 56, 3055-3061, 1996.

11. Hu, S., Shively, L., Raubitscheck, A. A., Sherman, M., Williams, L. E., Wong, J. Y. C., Shively, J. E., and Wu, A. M. Minibody: A novel engineered anti-CEA antibody fragment (single-chain Fv-C_H3) which exhibits rapid, high-level targeting of zenografts. Cancer Res. Vol. 56, 3055-3061, 1996.

12. Reeve, J. R., Jr., Eysselein, V. E., Rosenquist, G., Zeeh, J., Regner, U., Ho, F. J., Chew, P., Davis, M. T., Lee, T. D., Shively, J. E., Brazer, S. R., and Liddle, R. A. Evidence that CCK-58 has structure that influences its biological activity. Am. J. Physiol. Vol. 270, G860-8, 1996.

13. Swiderek, K. M., Lee, T. D., and Shively, J. E. Trace Structural Analysis of Proteins. *In:* B. L. Karger and W. S. Hancock (eds.), Meth. Enzymol., Vol. 271, pp. 68-86: Spectrum Publisher Services, 1996.

14. Williams, L. E., Primus, F. J., Wong, J. Y. C., Wu, A. M., Odom-Maryon, T., Johnson, D. K., Hefta, L. J. F., Shively, J. E., and Raubitscheck, A. A. Biodistribution of an In-111- or Y-90-labeled chimeric anti-CEA monoclonal antibody (T84.66) following its large-scale production in a bioreactor. Tumor Targeting. Vol. 2, 116-124, 1996.

15. Wu, A. M., Chen, W., Raubitscheck, A. A., Williams, L. E., Fischer, R., Hu, S., Odom-Maryon, T., Wong, J. Y. C., and Shively, J. E. Tumor localization of anti-CEA single-chain Fvs: Improved Targeting by dimeric species. Immunotechnology. Vol. 2, 21-36, 1996.

16. Bailey, J. M., Tu, O., Issai, G., Ha, A., and Shively, J. E. Automated carboxy-terminal sequence analysis of polypeptides containing C-terminal proline. Anal. Biochem. Vol. 224, 588-596, 1995.

17. Cano, L., Swiderek, K. M., and Shively, J. E. Comparison of ESI-MS, SIMS, and MALDI-TOF-MS for the primary Structure analysis of the CEA.11 H5 monoclonal Antibody. *In:* J. W. Crabb (ed.) Techniques in Protein Chemistry VI, pp. 21-30. San Diego, New York, Boston, London, Sydney, Tokyo, Toronto: Academic Press, Inc., 1995.

18. Chen, C. J., Li, L., Maruya, A., and Shively, J. E. In vitro and in vivo footprint analysis of the promoter of carcinoembryonic antigen in colon carcinoma cells. Effects of interferon-g treatment. Cancer Res. Vol. 55, 3873-3882, 1995.

19. Esteban, J. M., Raubitscheck, A., Felder, B., Williams, L. E., Wong, J. Y. C., and Shively, J. E. Breast tumor xenograft targeting and therapy studies using radiolabeled chimeric anti-CEA monoclonal antibody T84.66. Oncology Reports. Vol. 3, 237-242, 1995.

20. McCauley, L. D., Park, C. H., Lan, N. C., Tomich, J. M., Shively, J. E., and Gee, K. W. Benzodiazepines and peptides stimulate pregnenolone synthesis in brain mitochondria. Eur. J. Pharmacol. Vol. 276, 145-153, 1995.

21. Swiderek, K. M., Klein, M. L., Hefta, S. A., and Shively, J. E. Strategies for the removal of ionic and non-ionic detergents from protein and peptide mixtures for on- and off-line liquid chromatography mass spectrometry (LCMS). *In:* J. W. Crabb (ed.) Protein Chemistry, Vol. VI, pp. 267-275. San Diego, New York, Boston, London, Sydney, Tokyo, Toronto: Academic Press, Inc., 1995.

22. Wong, J. Y. C., Williams, L. E., Yamauchi, D. M., Odom-Maryon, T., Esteban, J. M., Neumaier, M., Wu, A. M., Johnson, D. K., Primus, F. J., Shively, J. E., and Raubitscheck, A. A. Initial experience evaluating ^{90}yttrium radiolabeled anti-CEA chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Research (suppl.). Vol. 55, 5929-5934, 1995.

23. Bailey, J. M. and Shively, J. E. A chemical method for the C-terminal sequence analysis of proteins. *In:* J. E. Shively (ed.) Micromethods for Protein Structural Analysis: A Companion to Methods in Enzymology, Vol. 6, pp. 334-350. San Diego: Academic Press, Inc., 1994.
24. Bailey, J. M. and Shively, J. E. Strategies for increasing the sensitivity of N-terminal sequence analysis. *In:* J. W. Crabb (ed.) Techniques in Protein Chemistry V, pp. 169-178. San Diego: Academic Press, Inc., 1994.
25. Chen, C.-J., Kane, R. R., Primus, F. J., Szalai, G., Hawthorne, M. F., and Shively, J. E. Preparation and characterization of oligomeric nido-carboranyl phosphate diester conjugate to anibody and antibody fragment for potential use in Boron Neutron Capture Therapy of solid tumor. Bioconj. Chem. Vol. 5, 557-654, 1994.
26. Collie, N. L., Walsh, J. H., Wong, H. C., Shively, J. E., Davis, M. T., Lee, T. D., and Reeve, J. R., Jr. Purification and sequence of rat oxyntomodulin. Proc Natl Acad Sci. Vol. 91, 9362-9366, 1994.
27. Esteban, J. M., Felder, B., Ahn, C., Simpson, J. F., Battifora, H., and Shively, J. E. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer. Vol. 74, 1575-1583, 1994.
28. Lewis, M. R., Raubitscheck, A., and Shively, J. E. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjugate Chem. Vol. 5, 565-576, 1994.
29. Ronk, M., Davis, M. T., Lee, T. D., Shively, J. E., and Hefta, S. A. Applications of tandem capillary HPLC in the isolation of proteins for characterization using microsequencing and mass spectrometry. *In:* J. W. Crabb (ed.) Techniques in Protein Chemistry V, Vol. V, pp. 259-261. San Diego: Academic Press, 1994.
30. Bailey, J. M., Rusnak, M., and Shively, J. E. Automated C-Terminal Sequencing of Peptides and Proteins. *In:* K. Imahori and F. Sakiyama (eds.), Methods in Protein Sequence Analysis, pp. 63-69. New York: Plenum Publishing Corp., 1993.
31. Bailey, J. M., Rusnak, M., and Shively, J. E. Compact protein sequencer for the C-terminal analysis of peptides and proteins. Anal. Biochemistry. Vol. 212, 366-374, 1993.
32. Beatty, B. G., Paxton, R. J., Hawthorne, M. F., Williams, L. E., Rickard-Dickson, K. J., Do, T., Shively, J. E., and Beatty, J. D. Pharmacokinetics of an anti-carcinoembryonic antigen monoclonal antibody conjugated to a bifunctional transition metal carborane complex (venus flytrap cluster) in tumor-bearing mice. J. Nucl. Med. Vol. 34, 1294-1302, 1993.
33. Esteban, J. M., Paxton, R., Mehta, P., Battifora, H., and Shively, J. E. Sensitivity and specificity of gold types 1-5 anti-carcinoembryonic antigen monoclonal antibodies. Human Pathology. Vol. 24, 322-328, 1993.
34. Gaida, F., Pieper, D., Roder, U. W., Shively, J. E., Wagener, C., and Neumaier, M. Molecular characterization of a cloned idiotypic cascade containing a network antigenic determinant specific for the human carcinoembryonic antigen. J. Biol. Chemistry. Vol. 268, 14138-14145, 1993.
35. Jessup, J. M., Kim, J. C., Thomas, P., Ishii, S., Ford, R., Shively, J. E., Durbin, H., Stanners, C. P., Fuks, A., Zhou, H., Hansen, H. J., Goldenberg, D. M., and Steele, J., G. Adhesion to carcinoembryonic antigen by human colorectal carcinoma cells involves at least two epitopes. Int. J. Cancer. Vol. 55, 262-268, 1993.
36. Knight, W. B., Swiderek, K. M., Sakuma, T., Calacay, J., Shively, J. E., Lee, T. D., Covey, B., Shushan, B., and Mumford, R. Electrospray Ionization Mass Spectrometry as a mechanical tool: The mass of human leucocyte elastase and a b-Lactam derived E-I complex. J. Amer. Chem. Soc. Vol. 32, 2031-2035, 1993.
37. Mahrenholz, A., Yeh, C. H., Shively, J. E., and Hefta, S. A. Microsequence analysis and mass spectral analysis of NCA-160, a CD15 positive neutrophil membrane

glycoprotein: Demonstration of identity with BGP1. J. Biol. Chem. Vol. 268, 13015-13018, 1993.
38. Sauter, S. L., Rutherfurd, S., Wagener, C., Shively, J. E., and Hefta, S. A. Identification of the glycosylatic sites on NCA-50, a CD66 cluster granulocyte glycoprotein, recognized by the type I fimbriae lectin from Escherichia coli. J. Biol. Chem. Vol. 268, 15510-15516, 1993.
39. Shenoy, N. R., Shively, J. E., and Bailey, J. M. Studies in C-terminal sequencing: New reagents for the synthesis of peptidylthiohydantoins. J. Protein Chemistry. Vol. 12, 195-205, 1993.